{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:45Z","timestamp":1784557065757,"version":"3.55.0"},"reference-count":15,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["eo.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"\n Summary<\/jats:title>\n Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described.<\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.<\/jats:p>\n <\/jats:list-item>\n \n It is recommended that patients treated with ICIs are observed by an endocrinologist.<\/jats:p>\n <\/jats:list-item>\n \n If side effects are treated accordingly, ICI therapy can continue.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/eo-22-0047","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T14:54:41Z","timestamp":1663858481000},"page":"K21-K24","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":5,"title":["Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab"],"prefix":"10.1530","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-5626","authenticated-orcid":true,"given":"Alexander","family":"Kreze","sequence":"first","affiliation":[{"name":"Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech Republic"},{"name":"Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat\u011bj","family":"Homer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Bare\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Klemperov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, The Bulovka University Hospital, Praha, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Journal of Experimental Medicine","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective","volume":"1","author":"Burke","year":"2020","unstructured":"Burke KPGrebinoski SSharpe AHVignali DAA2020Understanding adverse events of immunotherapy: a mechanistic perspective. Journal of Experimental Medicine1 e20192179. (https:\/\/doi.org\/10.1084\/jem.20192179)"},{"key":"bib2","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French Endocrine Society Guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","unstructured":"Castinetti FAlbarel FArchambeaud FBertherat JBouillet BBuffier PBriet CCariou BCaron PChabre O2019French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrine-Related Cancer26G1\u2013G18. (https:\/\/doi.org\/10.1530\/ERC-18-0320)10.1530\/ERC-18-0320"},{"issue":"Supplement 1","key":"bib3","series-title":"Endocrine Reviews","article-title":"Primary hypoparathyroidism: a new endocrine immune related adverse event (irAEs) secondary to combination treatment with PD-1 and CLA-4 checkpoint inhibitors","volume":"38","author":"Cubb","year":"2017","unstructured":"Cubb TPatel S2017Primary hypoparathyroidism: a new endocrine immune related adverse event (irAEs) secondary to combination treatment with PD-1 and CLA-4 checkpoint inhibitors. Endocrine Reviews38 (Supplement 1). (https:\/\/doi.org\/10.1093\/edrv\/38.supp.1)"},{"key":"bib4","series-title":"Journal for ImmunoTherapy of Cancer","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","unstructured":"Dadu RRodgers TETrinh VAKemp EHCubb TDPatel SSimon JMBurton EMTawbi H2020Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. Journal for ImmunoTherapy of Cancer8 e000687. (https:\/\/doi.org\/10.1136\/jitc-2020-000687)"},{"key":"bib5","series-title":"Medicina","first-page":"269","article-title":"Endocrinne dysfunction induced by immune checkpoint inhibitors","volume":"81","author":"Deligiannis","year":"2021","unstructured":"Deligiannis NGSosa SDanilowicz KRizzo LFL2021Endocrinne dysfunction induced by immune checkpoint inhibitors. Medicina81269\u2013278."},{"issue":"Supplement 1","key":"bib6","series-title":"Endocrine Reviews","article-title":"Nivolumab induced hypoparathyroidism","volume":"39","author":"Edd","year":"2018","unstructured":"Edd TTaufeeq MBuschur E2018Nivolumab induced hypoparathyroidism. Endocrine Reviews39 (Supplement 1). (https:\/\/doi.org\/10.1093\/edrv\/39.supp.1)"},{"key":"bib7","series-title":"Mayo Clinic Proceedings","first-page":"821","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","unstructured":"El Kawkgi OMLi DKotwal AWermers RA2020Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clinic Proceedings4821\u2013825. (https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.07.006)"},{"key":"bib8","series-title":"TouchREVIEWS in Endocrinology","first-page":"21","article-title":"Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies","volume":"17","author":"George","year":"2021","unstructured":"George ASFernandez CJEapen DPappachan JM2021Organ-specific adverse events of immune checkpoint inhibitor therapy, with special reference to endocrinopathies. TouchREVIEWS in Endocrinology1721\u201332. (https:\/\/doi.org\/10.17925\/EE.2021.17.1.21)"},{"key":"bib9","series-title":"Clinical Medicine","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.7861\/clinmed.2020-0827","article-title":"Endocrine complications of immunotherapies: a review","volume":"21","author":"Hattersley","year":"2021","unstructured":"Hattersley RNana MLansdown AJ2021Endocrine complications of immunotherapies: a review. Clinical Medicine21e212\u2013e222. (https:\/\/doi.org\/10.7861\/clinmed.2020-0827)10.7861\/clinmed.2020-0827"},{"key":"bib10","series-title":"Current Oncology","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3747\/co.27.5111","article-title":"Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy","volume":"27","author":"Khan","year":"2020","unstructured":"Khan OFMonzon J2020Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Current Oncology27S43\u2013S50. (https:\/\/doi.org\/10.3747\/co.27.5111)10.3747\/co.27.5111"},{"key":"bib11","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1210\/clinem\/dgaa092","article-title":"Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","unstructured":"Lupi IBrancatella ACetani FLatrofa FKemp EHMarcocci C2020Activating antibodies to the calcium-sensing receptor in immunotherapy-induced hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism1051581\u20131588. (https:\/\/doi.org\/10.1210\/clinem\/dgaa092)10.1210\/clinem\/dgaa092"},{"key":"bib12","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","unstructured":"Piranavan PLi YBrown EKemp EHTrivedi N2019Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. Journal of Clinical Endocrinology and Metabolism104550\u2013556. (https:\/\/doi.org\/10.1210\/jc.2018-01151)10.1210\/jc.2018-01151"},{"key":"bib13","series-title":"Journal for ImmunoTherapy of Cancer","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","unstructured":"Trinh BSanchez GOHerzig PL\u00e4ubli H2019Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. Journal for ImmunoTherapy of Cancer7 52. (https:\/\/doi.org\/10.1186\/s40425-019-0528-x)"},{"key":"bib14","series-title":"Journal of Oncology Practice","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi","year":"2018","unstructured":"Umeguchi HTakenoshita HInoue HKurihara YSakaguchi CYano SHasuzawa NSakamoto SSakamoto RAshida K2018Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report. Journal of Oncology Practice14449\u2013451. (https:\/\/doi.org\/10.1200\/JOP.18.00076)10.1200\/JOP.18.00076"},{"key":"bib15","series-title":"American Journal of Emergency Medicine","doi-asserted-by":"publisher","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","unstructured":"Win MAThien KZQdaisat AYeung SJ2017Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. American Journal of Emergency Medicine351039.e5\u20131039.e7. (https:\/\/doi.org\/10.1016\/j.ajem.2017.02.048)10.1016\/j.ajem.2017.02.048"}],"container-title":["Endocrine Oncology"],"original-title":[],"link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/2\/1\/EO-22-0047.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/2\/1\/EO-22-0047.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/2\/1\/EO-22-0047.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:50:25Z","timestamp":1784555425000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/eo\/article\/2\/1\/K21-K24\/1518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":15,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eo-22-0047","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}